It seems complicated to meet medical products that become a blockbuster in their first year of release.
According to IQVIA, none of the new products launched this year exceeded KRW 10 billion (USD 9.24 million) or KRW 5billion (USD 4.62 million) in cumulative sales by the Q3.
A total of 10 new products posted more than KRW 1 billion (USD 924,000) in sales, and Dukaro (Boryung Pharmaceutical) was the only one to exceed KRW 4 billion (USD 3.7 million).
Followed by Dukaro, Finasteride (original product name: Propecia, MSD) generic Momopecia (TheU Pharmaceutical) had an average quarterly sales of more than KRW 1 billion at KRW 3.2 billion (USD 2.9 million).
Evenity (Amgen Korea) and Verzenio (Lily Korea), which recently got insurance coverage, made KRW 2.7 billion (USD 2.5 million) and KRW 2.6 billion (USD 2.4 million) in sales by Q3.
The Trifluridine/Tipiracil combined oral medication Lonsurf (Jeil Pharmaceutical Co.), which emerged as a new option for colorectal cancer, also reached more than KRW 2 billion (USD 1.85 million).
Furthermore, the first generic of the SR Mirabegron (original product name: Betmiga PR), which is an overactive bladder drug, Mirabek (Hanmi Pharmaceutical Co.) and Selebeta (Chong Kun Dang Pharmaceutical Corp.) have surpassed KRW 1 billion.
At the same time, the obesity drug Orlistat (original product name: Xenical, Chong Kun DangㆍRoche) generic Zenirow (Hutecs), Botulinum Toxin Liztox (Huons Global), and Magnesium liquid type Mag-B Speed Solution (Yuhan Corp.) made more than KRW 1 billion in sales.
